Advertisement

Sexual health and rehabilitation after ovarian suppression treatment (SHARE-OS): a clinical intervention for young breast cancer survivors

  • Sharon L. BoberEmail author
  • E. Fine
  • C. J. Recklitis
Article

Abstract

Purpose

Each year, thousands of young breast cancer (BC) patients confront the difficult decision to medically suppress ovarian function and undergo abrupt, premature menopause to reduce risk of cancer recurrence. Unlike natural menopause, young women undergoing ovarian suppression (OS) face severe and disruptive side effects. Profound sexual dysfunction is one of the most prevalent, distressing side effects of OS treatment. Unmanaged sexual dysfunction is also a primary predictor of non-adherence to this potentially life-saving treatment. We developed and tested a brief, psychosexual intervention targeted to manage sexual dysfunction and psychological distress after OS in young BC survivors.

Methods

Twenty young BC survivors with sexual dysfunction received a single 4-h group intervention that included sexual health rehabilitation, body awareness exercises, and mindfulness-based cognitive therapy (MBCT) skills followed by a single tailored booster telephone call 1-month later. Assessment of female sexual function and psychological distress was completed at baseline and 2 months post-intervention.

Results

Analyses examined changes pre- to post-intervention. Female sexual health improved significantly from baseline to follow-up (n = 19, p < 0.02). Anxiety was also significantly improved at the 2-month (p < 0.000) timepoint, compared with baseline 1. Moderate-to-large effect sizes were observed regarding changes in sexual function and psychological distress.

Conclusions

Significant improvements in sexual functioning and psychological distress were observed 2 months post-intervention.

Implications for Cancer Survivors

These results demonstrate that delivery of a targeted intervention in brief, low-intensity group setting is a promising model for reducing distressing sexual dysfunction in young BC survivors on OS treatment.

Keywords

Sexual health Breast cancer Sexual rehabilitation 

Notes

Compliance with ethical standards

The project received IRB approval.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Graziottin A, Basson R. Sexual dysfunction in women with premature menopause. Menopause. 2004;11(6 Pt 2):766–77.CrossRefPubMedGoogle Scholar
  2. 2.
    Partridge AH. Cancer survivorship and the young breast cancer patient: addressing the important issues. Oncologist. 2013;18(8):e19–20.  https://doi.org/10.1634/theoncologist.2013-0300.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Frechette D, Paquet L, Verma S, Clemons M, Wheatley-Price P, Gertler SZ, et al. The impact of endocrine therapy on sexual dysfunction in postmenopausal women with early stage breast cancer: encouraging results from a prospective study. Breast Cancer Res Treat. 2013;141(1):111–7.  https://doi.org/10.1007/s10549-013-2659-y.CrossRefPubMedGoogle Scholar
  4. 4.
    Ribi K, Luo W, Bernhard J, Francis PA, Burstein HJ, Ciruelos E, et al. Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: patient-reported outcomes in the suppression of ovarian function trial. J Clin Oncol. 2016;34:1601–10.  https://doi.org/10.1200/JCO.2015.64.8675.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Bober SL, Recklitis CJ, Michaud AL, Wright AA. Improvement in sexual function after ovarian cancer: effects of sexual therapy and rehabilitation after treatment for ovarian cancer. Cancer. 2017;124:176–82.  https://doi.org/10.1002/cncr.30976.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Bober SL, Recklitis CJ, Bakan J, Garber JE, Patenaude AF. Addressing sexual dysfunction after risk-reducing salpingo-oophorectomy: effects of a brief, psychosexual intervention. J Sex Med. 2015;12(1):189–97.  https://doi.org/10.1111/jsm.12713.CrossRefPubMedGoogle Scholar
  7. 7.
    Syrjala KL, Schroeder TC, Abrams JR, Atkins TZ, Brown WS, Sanders JE, et al. Sexual function measurement and outcomes in cancer survivors and matched controls. J Sex Res. 2000;37(3):213–25.  https://doi.org/10.1080/00224490009552042.CrossRefGoogle Scholar
  8. 8.
    Baser RE, Li Y, Carter J. Psychometric validation of the Female Sexual Function Index (FSFI) in cancer survivors. Cancer. 2012;118(18):4606–18.  https://doi.org/10.1002/cncr.26739.CrossRefPubMedGoogle Scholar
  9. 9.
    Recklitis CJ, Parsons SK, Shih MC, Mertens A, Robison LL, Zeltzer L. Factor structure of the brief symptom inventory-18 in adult survivors of childhood cancer: results from the childhood cancer survivor study. Psychol Assess. 2006;18(1):22–32.  https://doi.org/10.1037/1040-3590.18.1.22.CrossRefPubMedGoogle Scholar
  10. 10.
    Brotto LA, Yule M, Breckon E. Psychological interventions for the sexual sequelae of cancer: a review of the literature. J Cancer Surviv. 2010;4(4):346–60.  https://doi.org/10.1007/s11764-010-0132-z.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Dana-Farber Cancer InstituteBostonUSA
  2. 2.Harvard Medical SchoolBostonUSA

Personalised recommendations